| |
| DATE |
TITLE |
| October 29, 2008 |
IRX Therapeutics to Present at BIO Investor Forum |
| July 22, 2008 |
IRX Therapeutics Announces Results of Phase 2 Study for IRX-2 |
| July 15, 2008 |
IRX Therapeutics to Present Phase 2 Results at 7th International Conference on Head and Neck Cancer |
| June 3, 2008 |
IRX Therapeutics Completes $25 Million
Series A Preferred Stock Offering |
| May 2, 2008 |
IRX Therapeutics to Present Phase 2 Results at
3rd European Conference on Head & Neck Oncology |
| January 3, 2008 |
IRX Therapeutics to Present at the
26th Annual JP Morgan Healthcare Conference |
| October 4, 2007 |
Declan P. Doogan, M.D. joins IRX Therapeutics as Advisor on Global Product Development |
| May 24, 2007 | IRX Therapeutics Completes Second $12.5 Million Convertible Note Offering |
| March 16, 2007 | IRX Therapeutics Presents at the 27th Annual Cowen and Company Health Care Conference |
| January 16, 2007 | IRX Therapeutics Names John W. Hadden II President and CEO |
| January 5, 2007 | IRX Therapeutics to Present at the 25th Annual JP Morgan Healthcare Conference |
| November 28, 2006 | IRX Therapeutics Announces that Jean Louis Lefebvre, M.D. Has Joined its Medical Advisory Board |
| March 29, 2006 | IRX Therapeutics Raises $12.5 Million; Adds Frank J. Loverro to its Board of Directors |
| October 17, 2005 | IRX Therapeutics Enrolls First Patients in IRX-2 Phase II Head and Neck Cancer Study |
| May 5, 2005 | IRX Therapeutics Announces the Election of John T. Spitznagel As Chairman of its Board of Directors |
|
